Literature DB >> 8273757

Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children.

A B Martin1, A Garson, J C Perry.   

Abstract

When the QT interval is prolonged in a patient with structural heart disease, there is a question of whether the QT interval prolongation is the result of coexistent long QT interval syndrome or ventricular hypertrophy. The purpose of this study was to assess whether QT interval prolongation can be attributed to ventricular hypertrophy/dilation alone. Electrocardiograms (ECGs) of 25 children in each of six echocardiographically proven groups (right ventricular hypertrophy, left ventricular hypertrophy, biventricular hypertrophy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and normals) were analyzed. All patients had QRS interval durations < 100 msec, and patients with ventriculotomies were excluded. No patients in the normal group had a QTc interval > or = 0.45 sec. Eight (32%) of 25 patients with dilated cardiomyopathy had a QTc interval > or = 0.45 sec (p = 0.007 vs normal), 6 (24%) of 25 patients with hypertrophic cardiomyopathy had a QTc interval > or = 0.45 sec (p = 0.03 vs normal), and 2 of 25 patients each with right ventricular hypertrophy, left ventricular hypertrophy, and biventricular hypertrophy had a QTc interval > or = 0.45 sec (p = NS vs normal). There was no relation of the QTc interval to age, QRS duration, T-wave axis, or heart rate in any group. In the dilated cardiomyopathy group, there was no relationship of QTc interval to age, shortening fraction, or left ventricular end diastolic dimension. In conclusion, (1) a significant number of patients (24% to 32%) with dilated or hypertrophic cardiomyopathy may have a long QTc interval on the surface ECG, and (2) ventricular hypertrophy/dilation may be additional rare causes of acquired prolongation of the QT interval.

Entities:  

Mesh:

Year:  1994        PMID: 8273757     DOI: 10.1016/0002-8703(94)90510-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

Review 1.  The significance of QT interval in drug development.

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Dilated cardiomyopathy masquerading as long QT syndrome.

Authors:  J Walls; A Dipchand; S Sanatani
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

3.  Heart rate-corrected QT interval and QT dispersion in patients with pulmonary hypertension.

Authors:  Zhang Hong-liang; Luo Qin; Liu Zhi-hong; Zhao Zhi-hui; Xiong Chang-ming; Ni Xin-hai; He Jian-guo; Wei Ying-jie; Zhang Shu
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

4.  A mutation in TNNC1-encoded cardiac troponin C, TNNC1-A31S, predisposes to hypertrophic cardiomyopathy and ventricular fibrillation.

Authors:  Michelle S Parvatiyar; Andrew P Landstrom; Cicero Figueiredo-Freitas; James D Potter; Michael J Ackerman; Jose Renato Pinto
Journal:  J Biol Chem       Date:  2012-07-18       Impact factor: 5.157

5.  Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy.

Authors:  Jonathan N Johnson; Camilla Grifoni; J Martijn Bos; Maha Saber-Ayad; Steve R Ommen; Stefano Nistri; Franco Cecchi; Iacopo Olivotto; Michael J Ackerman
Journal:  Eur Heart J       Date:  2011-02-22       Impact factor: 29.983

6.  Regulation of the human ether-a-go-go-related gene (hERG) channel by Rab4 protein through neural precursor cell-expressed developmentally down-regulated protein 4-2 (Nedd4-2).

Authors:  Zhi Cui; Shetuan Zhang
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

Review 7.  Zebrafish genetic models for arrhythmia.

Authors:  David J Milan; Calum A Macrae
Journal:  Prog Biophys Mol Biol       Date:  2009-01-31       Impact factor: 3.667

8.  Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization.

Authors:  David J Milan; Albert M Kim; Jeffrey R Winterfield; Ian L Jones; Arne Pfeufer; Serena Sanna; Dan E Arking; Adam H Amsterdam; Khaled M Sabeh; John D Mably; David S Rosenbaum; Randall T Peterson; Aravinda Chakravarti; Stefan Kääb; Dan M Roden; Calum A MacRae
Journal:  Circulation       Date:  2009-08-03       Impact factor: 29.690

Review 9.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  The usefulness of surface electrocardiogram as a prognostic predictor in children with idiopathic dilated cardiomyopathy.

Authors:  June Huh; Chung Il Noh; Yong Soo Yun
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.